Shots:

• The P-II (IDeate-Lung01) study is assessing ifinatamab deruxtecan in ES-SCLC patients previously treated with 1-3L of therapies, to receive 8mg/kg or 12mg/kg (part 1), & at least 2L of therapy, to receive the recommended 12mg/kg (part 2)
• Results showed cORR: 54.8% with 23 PRs (12mg/kg) & 26.1% with 1 CR and 11 PRs (8mg/kg), mDoR: 4.2mos. & 7.9mos., DCR: 90.5% & 80.4%, mPFS: 5.5mos. & 4.2mos. and mOS: 11.8mos. & 9.4mos. The 12mg/kg dose is selected for the expansion phase
• In patients with brain target lesions intracranial ORRs were 50.0% with 3 PRs (12mg/kg, n=10) & 66.7% with 2 PRs (8mg/kg, n=6), 2 CRs were found in each cohort. Stable disease was observed in 5 (12mg/kg) & 2 cases (8mg/kg)

Ref: Merck | Image: Merck & Daiichi Sankyo

Related News:- Merck and Daiichi Sankyo Report the Initiation of P-III (IDeate-Lung02) Study of Ifinatamab Deruxtecan to Treat Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com